(0)サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1672316

生物製剤の世界市場レポート 2025年

Biologics Global Market Report 2025

出版日
ページ情報
英文 400 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.94円
生物製剤の世界市場レポート 2025年
出版日: 2025年03月03日
発行: The Business Research Company
ページ情報: 英文 400 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

生物製剤市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）15.0％で1兆682億4,000万米ドルに成長します。予測期間の成長は、資金調達の増加、技術の進歩、医療へのアクセスの増加、経口生物製剤開発のための旺盛な研究開発活動、注射よりも錠剤への傾倒、生物製剤の旺盛なパイプラインの増加などに起因しています。予測期間中の主要動向としては、規制の改正や緩和による新規・改良型生物製剤の開発、生物製剤開発へのシフト、革新的な生物製剤開発のための研究開発投資、複雑な疾患の治療のための生物製剤の研究開発投資などが挙げられます。

個別化医療に対する需要の高まりは、世界の生物製剤市場を大きく後押ししています。精密医療としても知られる個別化医療は、各患者のユニークな特徴に基づいて医療をカスタマイズする医療アプローチです。この手法により、生物学的療法を患者固有の遺伝的・臨床的プロファイルに合わせて調整することが可能になり、医療の状況を一変させています。例えば、2024年2月、米国を拠点とする病院・医療組織である個別化医療連合（Personalized Medicine Coalition）は、2023年にFDAが希少疾患患者のために16の新しい個別化治療を承認したと報告しました。その結果、個別化医療に対する需要の高まりが、今後の生物製剤市場の拡大を牽引することになります。

技術は、今期も市場拡大の原動力として際立っています。特に生理学シミュレーション・モデリングは大きく発展する見込みであり、市場開拓に貢献すると予想されます。このセグメントの進歩は効率化を約束するものであり、生物製剤市場の企業はこうした進歩の恩恵を受ける可能性が高いです。注目すべき事例としては、Eli LillyやPfizerなどの製薬大手がAmazonのElastic Compute Cloud（EC2）プラットフォームを採用していることが挙げられます。これらの企業は、初期の創薬におけるシミュレーションモデルの実施にこの技術を活用し、シミュレーションに要する時間を大幅に短縮しています。例えば、従来は数週間かかっていた作業を数時間で完了できるようになりました。リリーのオープンイノベーション創薬プログラムのような取り組みは、生物製剤研究開発強化への取り組みをさらに強調するものです。このような技術的進歩により、プロセスの合理化、コストの削減、生物製剤の開発フェーズの加速が期待され、企業はより迅速に製品を市場に投入することができます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の生物製剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の生物製剤市場：成長率分析
  • 世界の生物製剤市場の実績：規模と成長、2019～2024年
  • 世界の生物製剤市場の予測：規模と成長、2024～2029年、2034年
  • 世界の生物製剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の生物製剤市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • モノクローナル抗体（MAbS）
  • 治療用タンパク質
  • ワクチン
  • 世界の生物製剤市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
  • ブランド医薬品
  • ジェネリック医薬品
  • 世界の生物製剤市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 経口
  • 非経口
  • その他
  • 世界の生物製剤市場：購入方法別、実績と予測、2019～2024年、2024～2029年、2034年
  • 処方薬
  • 市販薬
  • 世界の生物製剤市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院薬局
  • 小売薬局/ドラッグストア
  • その他
  • 世界の生物製剤市場、モノクローナル抗体（MAbs）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 裸モノクローナル抗体
  • 結合モノクローナル抗体
  • 二重特異性モノクローナル抗体
  • 世界の生物製剤市場、治療用タンパク質のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ホルモン
  • 酵素
  • サイトカイン
  • 融合タンパク質
  • 世界の生物製剤市場、ワクチンのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 生弱毒化ワクチン
  • 不活化ワクチン
  • サブユニットワクチン
  • mRNAワクチン
  • ウイルスベクターワクチン

第7章 地域別・国別分析

  • 世界の生物製剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の生物製剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 バングラデシュ市場

第16章 タイ市場

第17章 ベトナム市場

第18章 マレーシア市場

第19章 シンガポール市場

第20章 フィリピン市場

第21章 香港市場

第22章 ニュージーランド市場

第23章 西欧市場

第24章 英国市場

第25章 ドイツ市場

第26章 フランス市場

第27章 イタリア市場

第28章 スペイン市場

第29章 スペイン市場

第30章 オーストリア市場

第31章 ベルギー市場

第32章 デンマーク市場

第33章 フィンランド市場

第34章 アイルランド市場

第35章 オランダ市場

第36章 ノルウェー市場

第37章 ポルトガル市場

第38章 スウェーデン市場

第39章 スイス市場

第40章 東欧市場

第41章 ロシア市場

第42章 チェコ共和国市場

第43章 ポーランド市場

第44章 ルーマニア市場

第45章 ウクライナ市場

第46章 北米市場

第47章 米国市場

第48章 カナダ市場

第50章 南米市場

第51章 ブラジル市場

第52章 チリ市場

第53章 アルゼンチン市場

第54章 コロンビア市場

第55章 ペルー市場

第56章 中東市場

第57章 サウジアラビア市場

第58章 イスラエル市場

第59章 イラン市場

第60章 トルコ市場

第61章 アラブ首長国連邦市場

第62章 アフリカ市場

第63章 エジプト市場

第64章 ナイジェリア市場

第65章 南アフリカ市場

第66章 競合情勢と企業プロファイル

  • 生物製剤市場：競合情勢
  • 生物製剤市場：企業プロファイル
    • Merck & Co., Inc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Pfizer Inc.

第67章 その他の大手企業と革新的企業

  • Bristol Myers Squibb Company
  • Sanofi S.A.
  • GlaxoSmithKline Plc.
  • Eli Lilly and Company
  • Amgen Inc.
  • Wockhardt
  • Zydus Cadilla
  • China Biologic Products Holdings Inc.
  • ABLbio
  • Adimmune
  • Henlius
  • Innovent Biologics
  • Bio-Thera
  • Hisun Pharma
  • 3SBio

第68章 世界の市場競合ベンチマーキングとダッシュボード

第69章 主要な合併と買収

第70章 最近の市場動向

第71章 市場の潜在力が高い国、戦略

  • 生物製剤市場、2029年：新たな機会を提供する国
  • 生物製剤市場、2029年：新たな機会を提供するセグメント
  • 生物製剤市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第72章 付録

目次
Product Code: r25495

Biologics are medications derived from organic materials and are utilized to treat a diverse range of illnesses, particularly immune-related conditions such as Crohn's disease, psoriasis, ankylosing spondylitis, and rheumatoid arthritis. One intriguing aspect is that biologics are sourced from various natural materials, including carbohydrates, proteins, nucleic acids, or complex mixtures of these substances.

The primary types of biologics include monoclonal antibodies (MAbs), therapeutic proteins, and vaccines. Monoclonal antibodies, or mAbs, are engineered in laboratories to target specific infections. These biologics can be administered through various routes, including oral, parenteral, and others, and are distributed through channels such as hospital pharmacies, retail pharmacies/drug stores, and others.

The biologics market research report is one of a series of new reports from The Business Research Company that provides biologics market statistics, including biologics industry global market size, regional shares, competitors with a biologics market share, detailed biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the biologics industry. This biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biologics market size has grown rapidly in recent years. It will grow from $533.36 billion in 2024 to $610.25 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to aging population, government initiatives, ability to command high prices, and increased need for immunology.

The biologics market size is expected to see rapid growth in the next few years. It will grow to $1068.24 billion in 2029 at a compound annual growth rate (CAGR) of 15.0%. The growth in the forecast period can be attributed to increase in funding, technological advancements, increase in healthcare access, robust research and development activities for development of oral biologics, lean towards pills over injections, and increasing robust pipeline of biologics. Major trends in the forecast period include leveraging revised and less stringent regulations to develop new and improved biologics, shifting to biologic drug development, investing in R&D for the development of innovative biologics, and investing in research and development of biologics for the treatment of complex diseases.

The rising demand for personalized medicine is significantly boosting the global biologics market. Also known as precision medicine, personalized medicine is a healthcare approach that customizes medical treatment based on the unique characteristics of each patient. This method allows for the tailoring of biological therapies to align with a patient's specific genetic and clinical profile, thereby transforming the healthcare landscape. For instance, in February 2024, the Personalized Medicine Coalition, a U.S.-based hospital and healthcare organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, an increase from six approvals in 2022. Consequently, the growing demand for personalized medicine is driving the expansion of the biologics market in the future.

Technology stands out as a continued driving force behind market expansion in this period. Physiology simulation modeling, in particular, is poised for significant development and is anticipated to contribute to market growth. Advances in this field promise greater efficiencies, and companies within the biologics market are likely to benefit from such advancements. Notable instances include the adoption of Amazon's Elastic Compute Cloud (EC2) platform by pharmaceutical giants such as Eli Lilly and Pfizer. These companies utilize this technology for conducting simulation models in early drug discovery, significantly reducing the time required for simulations. For instance, tasks that traditionally took weeks can now be completed within hours. Initiatives such as Lilly's Open Innovation Drug Discovery program further underscore efforts to enhance biologics research and development. These technological advancements are expected to streamline processes, lower costs, and accelerate the development phase of biologics, enabling companies to introduce their products to market more swiftly.

The focus of major companies in the biologics industry on developing innovative products, such as oncology biosimilars, reflects their strategic initiatives to strengthen market positions and gain competitive advantages. Oncology biosimilars, specifically designed to treat cancer, are akin to existing biologic drugs and offer highly similar alternatives in terms of efficacy and safety. An example of this pursuit is seen in the collaboration between Biocon Biologics Limited and Viatris Inc., which led to the launch of Abevmy in Canada in May 2022. Abevmy is an oncology biosimilar utilized for cancer treatment, exhibiting similarity to an already authorized biological medicine.

The revisions made by the US Food and Drug Administration (FDA) in its regulations concerning biologics signify a shift toward eliminating outdated requirements. The alterations allow drug manufacturers to adopt new manufacturing technologies and testing capabilities. Specifically, the FDA has amended regulations to enable the sourcing of standard preparations, critical in ensuring the safety, purity, and potency of biologics, from sources beyond the FDA's Center for Biologics Evaluation and Research (CBER). Additionally, the FDA has removed the minimal potency limits rule (Section 610.21 of FDA code) pertaining to certain antibodies and antigens. Furthermore, updates in regulations (Section 610.53 of FDA code) concerning storage periods and conditions for biologics have been introduced. These regulatory amendments aim to enhance flexibility and promote the adoption of contemporary scientific technologies in the manufacturing processes of licensed biological products, fostering innovation and progress in the biologics industry.

Major companies operating in the biologics market include Merck & Co., Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Amgen Inc., Wockhardt, Zydus Cadilla, China Biologic Products Holdings Inc., ABLbio, Adimmune, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Biocon, Dr.Reddy's, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Tonghua Dongbao Pharmaceutical Co., China Regenerative Medicine International, Shanghai Fosun Pharmaceuticals, Bayer AG, Novartis AG, BiosanaPharma, WuXi, Teva UK Limited, AstraZeneca, Abbott Laboratories, Vectura Group, Fujifilm, Lonza, Seqens, Piramal Pharma Solutions, Corden Pharma, Procos SpA and BSP Pharmaceuticals., Microgen, Geropharm, Valenta, NovaMedica, SynBi, Rani Therapeutics, Enteris BioPharma, Allena Pharmaceuticals, Biogen Inc., Emisphere Technologies Inc., Biogen Inc., Apotex, Gilead Sciences

North America was the largest region in the biologics market in 2024. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biologics market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa

The biologics market consists of sales of tumor necrosis factor inhibitors, Interleukin inhibitors, B-cells inhibitors, and T-cells inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines
  • 2) By Drug Classification: Branded Drugs, Generic Drugs
  • 3) By Route Of Administration: Oral, Other Route Of Administration
  • 4) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs
  • 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other Distribution Channels
  • Subsegments:
  • 1) By Monoclonal Antibodies (MAbs): Naked Monoclonal Antibodies; Conjugated Monoclonal Antibodies; Bispecific Monoclonal Antibodies
  • 2) By Therapeutic Proteins: Hormones; Enzymes; Cytokines; Fusion Proteins
  • 3) By Vaccines: Live Attenuated Vaccines; Inactivated Vaccines; Subunit Vaccines; mRNA Vaccines; Viral Vector Vaccines
  • Companies Mentioned: Merck & Co., Inc.; AbbVie Inc.; F. Hoffmann-La Roche AG; Johnson & Johnson; Pfizer Inc.
  • Countries: Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biologics Market Characteristics

3. Biologics Market Trends And Strategies

4. Biologics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Biologics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Biologics Market Growth Rate Analysis
  • 5.4. Global Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Biologics Total Addressable Market (TAM)

6. Biologics Market Segmentation

  • 6.1. Global Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Monoclonal Antibodies (MAbS)
  • Therapeutic Proteins
  • Vaccines
  • 6.2. Global Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Branded Drugs
  • Generic Drugs
  • 6.3. Global Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Parenteral
  • Other Route Of Administration
  • 6.4. Global Biologics Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prescription-Based Drugs
  • Over-The-Counter Drugs
  • 6.5. Global Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies/ Drug Stores
  • Other Distribtuion Channels
  • 6.6. Global Biologics Market, Sub-Segmentation Of Monoclonal Antibodies (MAbs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Naked Monoclonal Antibodies
  • Conjugated Monoclonal Antibodies
  • Bispecific Monoclonal Antibodies
  • 6.7. Global Biologics Market, Sub-Segmentation Of Therapeutic Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormones
  • Enzymes
  • Cytokines
  • Fusion Proteins
  • 6.8. Global Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • mRNA Vaccines
  • Viral Vector Vaccines

7. Biologics Market Regional And Country Analysis

  • 7.1. Global Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biologics Market

  • 8.1. Asia-Pacific Biologics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biologics Market

  • 9.1. China Biologics Market Overview
  • 9.2. China Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biologics Market

  • 10.1. India Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biologics Market

  • 11.1. Japan Biologics Market Overview
  • 11.2. Japan Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biologics Market

  • 12.1. Australia Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biologics Market

  • 13.1. Indonesia Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biologics Market

  • 14.1. South Korea Biologics Market Overview
  • 14.2. South Korea Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Bangladesh Biologics Market

  • 15.1. Bangladesh Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.2. Bangladesh Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Bangladesh Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. Thailand Biologics Market

  • 16.1. Thailand Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. Thailand Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. Thailand Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Vietnam Biologics Market

  • 17.1. Vietnam Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Vietnam Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Vietnam Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. Malaysia Biologics Market

  • 18.1. Malaysia Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. Malaysia Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. Malaysia Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Singapore Biologics Market

  • 19.1. Singapore Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Singapore Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Singapore Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Philippines Biologics Market

  • 20.1. Philippines Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Philippines Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Philippines Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Hong Kong Biologics Market

  • 21.1. Hong Kong Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.2. Hong Kong Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Hong Kong Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. New Zealand Biologics Market

  • 22.1. New Zealand Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. New Zealand Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. New Zealand Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. Western Europe Biologics Market

  • 23.1. Western Europe Biologics Market Overview
  • 23.2. Western Europe Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. Western Europe Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. Western Europe Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. UK Biologics Market

  • 24.1. UK Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.2. UK Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. UK Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Germany Biologics Market

  • 25.1. Germany Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.2. Germany Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Germany Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. France Biologics Market

  • 26.1. France Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.2. France Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. France Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Italy Biologics Market

  • 27.1. Italy Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Italy Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Italy Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Spain Biologics Market

  • 28.1. Spain Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.2. Spain Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Spain Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Spain Biologics Market

  • 29.1. Spain Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.2. Spain Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Spain Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Austria Biologics Market

  • 30.1. Austria Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 30.2. Austria Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 30.3. Austria Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

31. Belgium Biologics Market

  • 31.1. Belgium Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 31.2. Belgium Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 31.3. Belgium Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

32. Denmark Biologics Market

  • 32.1. Denmark Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 32.2. Denmark Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 32.3. Denmark Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

33. Finland Biologics Market

  • 33.1. Finland Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 33.2. Finland Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 33.3. Finland Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

34. Ireland Biologics Market

  • 34.1. Ireland Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 34.2. Ireland Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 34.3. Ireland Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

35. Netherlands Biologics Market

  • 35.1. Netherlands Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 35.2. Netherlands Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 35.3. Netherlands Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

36. Norway Biologics Market

  • 36.1. Norway Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 36.2. Norway Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 36.3. Norway Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

37. Portugal Biologics Market

  • 37.1. Portugal Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 37.2. Portugal Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 37.3. Portugal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

38. Sweden Biologics Market

  • 38.1. Sweden Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 38.2. Sweden Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 38.3. Sweden Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

39. Switzerland Biologics Market

  • 39.1. Switzerland Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 39.2. Switzerland Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 39.3. Switzerland Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

40. Eastern Europe Biologics Market

  • 40.1. Eastern Europe Biologics Market Overview
  • 40.2. Eastern Europe Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 40.3. Eastern Europe Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 40.4. Eastern Europe Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

41. Russia Biologics Market

  • 41.1. Russia Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 41.2. Russia Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 41.3. Russia Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

42. Czech Republic Biologics Market

  • 42.1. Czech Republic Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 42.2. Czech Republic Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 42.3. Czech Republic Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

43. Poland Biologics Market

  • 43.1. Poland Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 43.2. Poland Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 43.3. Poland Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

44. Romania Biologics Market

  • 44.1. Romania Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 44.2. Romania Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 44.3. Romania Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

45. Ukraine Biologics Market

  • 45.1. Ukraine Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 45.2. Ukraine Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 45.3. Ukraine Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

46. North America Biologics Market

  • 46.1. North America Biologics Market Overview
  • 46.2. North America Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 46.3. North America Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 46.4. North America Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

47. USA Biologics Market

  • 47.1. USA Biologics Market Overview
  • 47.2. USA Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 47.3. USA Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 47.4. USA Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

48. Canada Biologics Market

  • 48.1. Canada Biologics Market Overview
  • 48.2. Canada Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 48.3. Canada Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 48.4. Canada Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 49.1. Mexico Biologics Market Overview
  • 49.2. Mexico Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 49.3. Mexico Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 49.4. Mexico Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

50. South America Biologics Market

  • 50.1. South America Biologics Market Overview
  • 50.2. South America Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 50.3. South America Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 50.4. South America Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

51. Brazil Biologics Market

  • 51.1. Brazil Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 51.2. Brazil Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 51.3. Brazil Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

52. Chile Biologics Market

  • 52.1. Chile Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 52.2. Chile Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 52.3. Chile Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

53. Argentina Biologics Market

  • 53.1. Argentina Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 53.2. Argentina Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 53.3. Argentina Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

54. Colombia Biologics Market

  • 54.1. Colombia Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 54.2. Colombia Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 54.3. Colombia Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

55. Peru Biologics Market

  • 55.1. Peru Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 55.2. Peru Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 55.3. Peru Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

56. Middle East Biologics Market

  • 56.1. Middle East Biologics Market Overview
  • 56.2. Middle East Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 56.3. Middle East Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 56.4. Middle East Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

57. Saudi Arabia Biologics Market

  • 57.1. Saudi Arabia Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 57.2. Saudi Arabia Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 57.3. Saudi Arabia Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

58. Israel Biologics Market

  • 58.1. Israel Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 58.2. Israel Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 58.3. Israel Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

59. Iran Biologics Market

  • 59.1. Iran Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 59.2. Iran Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 59.3. Iran Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

60. Turkey Biologics Market

  • 60.1. Turkey Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 60.2. Turkey Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 60.3. Turkey Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

61. United Arab Emirates Biologics Market

  • 61.1. United Arab Emirates Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 61.2. United Arab Emirates Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 61.3. United Arab Emirates Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

62. Africa Biologics Market

  • 62.1. Africa Biologics Market Overview
  • 62.2. Africa Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 62.3. Africa Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 62.4. Africa Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

63. Egypt Biologics Market

  • 63.1. Egypt Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 63.2. Egypt Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 63.3. Egypt Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

64. Nigeria Biologics Market

  • 64.1. Nigeria Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 64.2. Nigeria Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 64.3. Nigeria Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

65. South Africa Biologics Market

  • 65.1. South Africa Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 65.2. South Africa Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 65.3. South Africa Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

66. Biologics Market Competitive Landscape And Company Profiles

  • 66.1. Biologics Market Competitive Landscape
  • 66.2. Biologics Market Company Profiles
    • 66.2.1. Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.4. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 66.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

67. Biologics Market Other Major And Innovative Companies

  • 67.1. Bristol Myers Squibb Company
  • 67.2. Sanofi S.A.
  • 67.3. GlaxoSmithKline Plc.
  • 67.4. Eli Lilly and Company
  • 67.5. Amgen Inc.
  • 67.6. Wockhardt
  • 67.7. Zydus Cadilla
  • 67.8. China Biologic Products Holdings Inc.
  • 67.9. ABLbio
  • 67.10. Adimmune
  • 67.11. Henlius
  • 67.12. Innovent Biologics
  • 67.13. Bio-Thera
  • 67.14. Hisun Pharma
  • 67.15. 3SBio

68. Global Biologics Market Competitive Benchmarking And Dashboard

69. Key Mergers And Acquisitions In The Biologics Market

70. Recent Developments In The Biologics Market

71. Biologics Market High Potential Countries, Segments and Strategies

  • 71.1 Biologics Market In 2029 - Countries Offering Most New Opportunities
  • 71.2 Biologics Market In 2029 - Segments Offering Most New Opportunities
  • 71.3 Biologics Market In 2029 - Growth Strategies
    • 71.3.1 Market Trend Based Strategies
    • 71.3.2 Competitor Strategies

72. Appendix

  • 72.1. Abbreviations
  • 72.2. Currencies
  • 72.3. Historic And Forecast Inflation Rates
  • 72.4. Research Inquiries
  • 72.5. The Business Research Company
  • 72.6. Copyright And Disclaimer